
Opinion|Videos|May 16, 2025
Balancing Treatment and Quality of Life: Adverse Events of First-Line Agents in NSCLC
Author(s)Lauren Ledbetter, PharmD, BCOP
A panelist discusses how EGFR tyrosine kinase inhibitors (TKIs) commonly cause dermatologic toxicities (including acneiform rash, dry skin, photosensitivity, and paronychia) and diarrhea, which can significantly impact patients’ quality of life by causing physical discomfort, affecting appearance, and limiting daily activities.
Advertisement
Episodes in this series

Adverse Events of EGFR TKIs: Summary for Physicians
Based on the transcript, the most common adverse events associated with EGFR TKIs are:
Dermatologic Toxicities
- Acneiform rash: Typically affects face, upper chest, back, and shoulders
- More common in men than in women
- Can range from mild to severe with potential for superimposed infection
- Management varies by grade/body surface area affected
- Severe cases may require topical and oral antibiotics
- Dry skin: Requires regular moisturizing with creamy products
- Associated itching can disrupt sleep and impact quality of life
- Paronychia: Presentations include nail flaking, cracking, nail bed/cuticle inflammation
- Can progress to abscess formation and nail loss in severe cases
- Management options include vinegar soaks and dermatology referral
- Photosensitivity: Increased skin sensitivity to sunlight
Gastrointestinal Effects
- Diarrhea: Second most common adverse event
- Ranges from increased frequency with formed stool to loose/watery diarrhea
- Associated urgency significantly impacts quality of life
- Patients may limit activities due to unpredictability
Quality-of-Life Impact
- Dermatologic toxicities may cause embarrassment, leading to social isolation
- Diarrhea can restrict patients’ ability to leave home
- Both categories of adverse effects may necessitate dose adjustments
This summary highlights the importance of proactive symptom management to maintain treatment efficacy and patient quality of life.
Advertisement
Related to this article

BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.

A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.

Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.

American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.

fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.

Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.

A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
Advertisement
Advertisement
Trending on Pharmacy Times
1
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
2
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5


